Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.

A first-in-class molecule called HLX79/E-602, when combined with rituximab, achieved a 100% total response rate in patients with membranous nephropathy at the highest dose by week 36. The combination also cut the median time to first response from 11 weeks down to just 3 weeks compared to rituximab alone. A larger phase 2b trial is now in the works.
A novel first-in-class therapy is turning heads in nephrology. HLX79/E-602 (efgitasialase alfa), a human sialidase-Fc fusion protein that strips sialic acid from immune cells, was tested alongside rituximab in a phase 2a trial for adults with primary membranous nephropathy — a kidney disease where current treatments often work slowly and inconsistently.
The trial enrolled 26 adults randomized to one of three doses of HLX79/E-602 plus rituximab, or rituximab alone. At week 36, the highest dose group (30 mg/kg) hit a 100% total response rate, compared to just 50% for rituximab alone. Even more striking: the median time to first response was 3 weeks in the top-dose group vs. 11.1 weeks with rituximab alone. Safety profiles were comparable across groups, with serious adverse events occurring only in the rituximab-alone arm.
By the Numbers:
Why it matters: Membranous nephropathy patients often wait months to see if their treatment is working. This combo therapy could dramatically speed up responses and improve outcomes — and researchers are already eyeing its potential in lupus membranous nephropathy and other B-cell-driven autoimmune diseases.